What is Dr Reddy's Laboratories Accounts Receivable?
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Dr Reddy's Laboratories's accounts receivables for the quarter that ended in Dec. 2023 was R$4,615 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Dr Reddy's Laboratories's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 99.18.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Dr Reddy's Laboratories's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was R$3.33.
Dr Reddy's Laboratories Accounts Receivable Historical Data
The historical data trend for Dr Reddy's Laboratories's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories Accounts Receivable Calculation
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
Dr Reddy's Laboratories Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Dr Reddy's Laboratories's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Dr Reddy's Laboratories's accounts receivable are only considered to be worth 75% of book value:
Dr Reddy's Laboratories's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Dr Reddy's Laboratories Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Dr Reddy's Laboratories (BSP:R1DY34) Business Description
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:R1DY34 has been successfully added to your 